Other

Slovak government softens regulation of CBD (cannabidiol)

Zuzana Hecko

On 21 August 2019 the Slovak government introduced a draft law which deletes CBD (cannabidiol) from the list of psychotropic substances and therefore makes CBD a non-regulated substance. CBD has been included in the list of psychotropic substances (category II) in Act No. 139/1998 (the  Narcotics Act) since 2011. It was included on the list Read More

Key developments in relation to new Chinese IP tribunal rule and Chinese patent law amendment

David Shen

Recently, there have been some key developments in the intellectual property sphere in China that may be relevant to life sciences clients.  Below we report on the new Chinese IP tribunal rule and an important Chinese patent law amendment. New Chinese IP tribunal rule The Standing Committee of the National People’s Congress previously announced the Read More

China announces pilot scheme for pharmaceutical tendering with minimum procurement quantities

David Shen

On 15 November 2018 the Joint Procurement Office (JPO) published its Paper on Centralized Drug Procurement in “4+7 Cities” (the Paper) which launched the national pilot scheme for tendering with minimum procurement quantities. The pilot scheme will be carried out in 11 cities: Beijing, Tianjin, Shanghai, Chongqing, Shenyang, Dalian, Xiamen, Guangzhou, Shenzhen, Chengdu and Xian, Read More

China – Data compliance in the life sciences sector

David Shen

China’s Ministry of Science and Technology (MOST) recently announced administrative sanctions against six entities for breach of the Provisional Measures for the Administration of Human Genetic Resources (Measure). In the 20 years since the Measure was implemented, this is the first time that MOST has announced any enforcement action. A closer look at the MOST Read More

China’s new anti-bribery agency announces pharma probe

David Shen

China’s State Administration for Market Regulation (SAMR) has announced the launch of a nationwide campaign to crack down on unfair competition and commercial bribery in the pharmaceutical, medical device and educational sectors. The campaign comes at a time when the Chinese government has enacted key amendments to its Anti-Unfair Competition Law (AUCL) and is gearing Read More